Stanford will rename campus spaces named for David Starr Jordan and relocate statue depicting Louis Agassiz
By Chris Peacock,
Stanford News
| 10. 07. 2020
Stanford will rename campus features named after David Starr Jordan and take actions to provide the public with a more complete view of his complex history, which includes not only his seminal leadership as the university’s founding president but also his parallel leadership in promoting eugenics.
The university will also relocate from the façade of Jordan Hall a statue of Jordan’s mentor, Louis Agassiz.
The decision follows a review conducted this summer by a committee of faculty, staff, students and alumni. The university’s Board of Trustees, acting on a recommendation by President Marc Tessier-Lavigne, approved these steps:
- Removing Jordan’s name from Jordan Hall, current home of the Department of Psychology; Jordan Quad and Jordan Modulars, near Panama Street and Campus Drive West; and Jordan Way in the Stanford Medical Center area;
- Relocating a statue of Agassiz from Jordan Hall to a location where it can be given appropriate context; and
- Developing an active effort to better explain the full range of Jordan’s legacy and contributions, beginning with an informational plaque in Jordan Hall and extending to additional efforts such as...
Related Articles
Since the “CRISPR babies” scandal in 2018, no additional genetically modified babies are known to have been born. Now several techno-enthusiastic billionaires are setting up privately funded companies to genetically edit human embryos, with the explicit intention of creating genetically modified children.
Heritable genome editing remains prohibited by policies in the overwhelming majority of countries that have any relevant policy, and by a binding European treaty. Support for keeping it legally off limits is widespread, including among scientists...
By Angus Liu, Fierce Pharma | 06.16.2025
A second patient has died following treatment with Sarepta Therapeutics’ Elevidys, raising more doubts about the Duchenne muscular dystrophy (DMD) gene therapy’s safety profile.
Sarepta and its ex-U.S. partner Roche reported the death early Sunday. Like the first case, disclosed...
By Sophie Alexander and Ike Swetlitz, Bloomberg | 06.25.2025
A California-startup focused on genetically editing human embryos — a step toward creating so-called designer babies — is raising money as many of Silicon Valley’s ultra-rich turn their attention to one of the most controversial technologies in medicine.
Bootstrap Bio...
